BERWYN, Pa.--(BUSINESS WIRE)--Formula Pharmaceuticals, Inc. (“Formula”) today announced the appointment of leading experts to its newly formed scientific advisory board (SAB). The SAB will serve as a strategic resource to Formula as it continues to develop Chimeric Antigen Receptor (CAR) immunotherapies leveraging Cytokine Induced Killer cells targeting cancer and autoimmune disease. “We are very excited working with Drs. Robert Negrin, Katy Rezvani and David Scheinberg as founding members of o
| < Prev | Next > |
|---|
